Ryuichi_Ida

PDF Upload


Basic Structure of
Ethics Governance of Biobank
Ryuichi IDA
Member, Council on Bioethics, Japan Medical Association
Distinguished Visiting Professor, Doshisha university, Japan
Expert Conference on the Revision of the Declaration of Helsinki
World Medical Association
28/02 – 1/013/2013, Imperial Hotel Tokyo. Tokyo, Japan
* The view expressed in this presentation is strictly my personal one, and not
necessarily represent the opinion of the Japan Medical Association.

Characteristics of Biobank
– Need of new ethical structure
=Governance
! Large scale collections (population based)
! Collection and storage of human materials
together with personal information
! Samples stored anonymous but linked
! Multiple use
! Genomic information analyzed
Questions concerning establishment
and management
! Concern of the general public : consensus
! Anonymized but linked samples and data
! Recruitment
! New type of consent
! Confidentiality management
! Other ethical issues
Concern of the general public
! Biobank with genetic/genomic database consists of
personal information that may reveal the privacy of each
participants as well as groups and communities.
! A large scale biobank should be initiated or established
in consultation with the general public of the nation or of
the population as well as other stakeholders.
(potential participants, representatives of the
population/community or focus groups, patients
groups, industry, State, researchers’ community)
! The extent of consultation will vary following the nature,
purpose, size and risks and sensitivity of the data and
the access.
! Methods of consultations are diverse.
! Importance should be given to build up a consensus to
establishment of a biobank
Recruitment
Recruitment of participants of a large scale is a heavy task.
1) Understanding and Support of the public
Long process from public announcement of the project,
through public informing meetings and consultations, to
informed consent procedure.
 2) Assurance of free will
Pressure of the community
(family, local community, state)

Prohibition of economic or social incentives
commercialization of human body and parts
Consent

Traditional informed consent procedure is inapplicable.
New type of consent is necessary
“One sample, for multiple purpose, stored for a long
time, anonymized but linked, and sometimes
periodically re-collected”
⇒”Linked anonymisation”
   Purposes of research using collected samples are not
defined and necessarily multiple.
“Broad Consent”(?)
The donor should be let understand what is a biobank,
and how samples and information are stored and used.
The weight of importance shifts to the confifdentiality.

Withdrawal

! Graduation of withdrawal should be considered.
consent – collection – during storage/before
use – during use (research) – before publication
– after publication
! After each stage, the effect of withdrawal will be
gradually limited.
disposal of samples : all, remaining, or made
unlinked and not disposed
erasure of data : all, part (kinds of data)

Linked anonymisation
! Samples and data should be kept anonymous.
! However, the connection is indispensable between the
donor and the samples and the data.
Follow the evolution of the donor’s health/disease
Revise the evaluation and the meaning of the
samples and data with new scientific developments
! Double randamised anonymisation is universally
recommended and recognised.
! Linkage to a specific participant necessary for adding the
samples and the data of the person concerned.
Continuous sampling and data collecting from the same
person is a key element for a biobank.
System for confidentiality management
! Measures of confidentiality protection should be clearly built.
Security of stored samples, security of the data
! Custody of Code Registry
   Designation of custodian of personal information
(identifiers, link between donor – personal data/information)
Duty of non-divulgation of information
Strictly protected data management (ex: stand-alone PC setting)
! Access limitation to the personal information
Limited access to personal information stored in the bank
Special authorization
Degree of access limitation may be proportionate of the purpose
The user (researchers and doctors) may only use personal
information which is deemed indispensable for a specific
research or application.
Need of Regulatory Regime

! For the efficient use of the sample and the
data stored in the biobank, a regulatory
regime should be established relating to
the purpose of use, intellectual property
rights, management of the whole biobank,
etc..

Basic Structure of Ethics
Governance of Biobank
! Triple principle
Transparency, accountability and traceability
! Three levels of control mechanism
Compliance control
quality control
access control
management control
Ethical control : Ethical review committee
“Public control” : public reporting and evaluation
! Need of national standard
Quality of the data
Degree of confidentiality protection
12
establishment

par-cipa-on

consent

storage

use

Public
 announcement
 /
 
Public
 debate
 
Public
 Consulta-on

Explanatory
 Mee-ng

Consent
 for
 Banking
 
Withdrawal
 -­‐
 total
 or
 par-al

Linkable
 anonymisa-on
 
Measures
 for
 personal
 data
 
protec-on

Access
 
Condi-on
 for
 use

BBDB
 
Biobank
 /Gene-c
 Database

Trans-­‐
 
parency
 

Account-­‐
ability
 

 
traceability
 
Compliance
 
measures
 
-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐
 
Quality
 
Access
 
Management
 
Ethical
 
Control
 
-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐
 
Ethics
 Review

Social
 Control
 
-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐
 
Publica-on
 
Evalua-on
 
State = Legal
 Basis
 and
 Uniform
 Standards

Governance
 of
 Biobank
 and
 Database

For
 DoH
 revision

Should
 DoH
 include
 provisions
 on
 biobank?
 

 
 
 
 The
 current
 stage
 of
 development
 of
 medical
 research
 requires
 
some
 ar-cles
 on
 biobank,
 whether
 or
 not
 men-oning
 “biobank”.
 

 
 
 A)
 If
 “biobank”
 should
 be
 men-oned,
 

 
 
 
 
 
 
 
 
 
 
 difficulty
 =
 defini-on
 

 
 
 B)
 If
 we
 remain
 providing
 only
 ar-cles
 regarding
 the
 issues
 at
 each
 
stages
 of
 biobank
 process
 without
 men-oning
 “biobank”,
 this
 
efficient
 tool
 of
 research
 may
 be
 confused
 with
 other
 procedures,
 
and
 such
 will
 not
 be
 for
 the
 protec-on
 and
 interest
 of
 the
 
par-cipants/pa-ents.
 
 
 
Possible
 solu-on
 

 
 
 
 
 Men-on
 “biobank,
 but
 leave
 regulatory
 framework
 to
 each
 
country’s
 laws
 and
 regula-ons.
 Soon
 or
 later,
 a
 kind
 of
 universal
 
 
standards
 
 will
 be
 established,
 in
 order
 to
 facilitate
 the
 flow
 of
 the
 
qualified
 data.

Merci.
Thank you.
ありがとうございました。